Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821732 | 0.89 | ALDH1A1 (0.57) | TSHRPOLBALDH1A1THRBCYP2C9 | |
| SCHEMBL3957116 | 0.88 | MMP8 (0.50) | MMP8SMN1; SMN2ELANEHPRT1TSHR | |
| SCHEMBL13915546 | 0.88 | MMP8 (0.50) | MMP8SMN1; SMN2ELANEHPRT1TSHR | |
| SCHEMBL19223394 | 0.87 | POLB (0.57) | MMP8ELANEHPRT1TSHRPOLB | |
| SCHEMBL6659344 | 0.86 | LTA4H (0.51) | MMP8SMN1; SMN2ELANEHPRT1TSHR | |
| SCHEMBL15242283 | 0.85 | MMP8 (0.56) | MMP8ELANEHPRT1POLBTP53 | |
| SCHEMBL352625 | 0.84 | MMP8 (0.47) | MMP8SMN1; SMN2ELANEHPRT1TSHR | |
| SCHEMBL352624 | 0.84 | MMP8 (0.47) | MMP8SMN1; SMN2ELANEHPRT1TSHR | |
| SCHEMBL24925125 | 0.84 | MMP8 (0.57) | MMP8ELANEHPRT1TSHRPOLB | |
| SCHEMBL656070 | 0.84 | MMP8 (0.57) | MMP8ELANEHPRT1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303527-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| CN-1443190-A | Matrix metalloproteinase inhibitors | LEO PHARM PROD LTD (DK) | 2003-09-17 | — | — | CN | disclosed |
| EP-1303527-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Leo Pharma A/S (DK) | 2003-04-23 | — | — | EP | disclosed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | disclosed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | disclosed |
| WO-2002006293-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA A/S (DK) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | MMP8 3/4885SMN1; SMN2 3764/4885ELANE 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.